Publications

 

 

 

2023 Selected Publications:

 

  1.  Charvátová S, Motais B, Czapla J, Cichoń T, Smolarczyk R, Walek Z, Giebel S, Hájek R, Bagó JR. Novel Local "Off-the-Shelf" Immunotherapy for the Treatment of Myeloma Bone Disease. Cells. 2023 Jan 30;12(3):448. doi: 10.3390/cells12030448. PMID: 36766789; PMCID: PMC9914109.

 

2022 Selected Publications:

 

  1. R. Termini, D. Zihala, E. Terpos, A. Pérez-Montaña, T. Jelinek, M. Raab, N. Weinhold, E. K. Mai, A. L. Grab, J. Corre, F. Vergez, A. Sacco, M. Chiarini, V. Giustini, A. Tucci, S. Rodríguez, C. Moreno, C. Perez, C. Maia, E. Martin-Sanchez, C. Guerrero, C. Botta, J.J. Garcés, A. Lopez, L.E. Tamariz-Amador, F. Prósper, J. Bargay, M.E. Cabezudo, E.M. Ocio, R. Hájek, J. Martinez-Lopez, F. Solano, R. Iglesias, A. Paiva, C. Geraldes, H. Matos Silva, C. Gomez, F. De Arriba, H. Ludwig, A. Garcia-Guiñon, M. Casanova, A. Alegre, V. Cabañas, M. Sirvent, A. Oriol, J. De la Rubia, J.A. Hernández-Rivas, L. Palomera, M. Sarasa, P. Rios, N. Puig, M.V. Mateos, J. Flores-Montero, A. Orfao, H. Goldschmidt, H. Avet-Loiseau, A. M. Roccaro, J. F. San-Miguel, B. Paiva, 2022. Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma. Clin Cancer Res; https://doi.org/10.1158/1078-0432.CCR-22-1594

  2. Johnstone M, Vinaixa D, Turi M, Morelli E, Anderson KC, Gulla A. Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma. Cells. 2022 Aug 14;11(16):2519. doi: 10.3390/cells11162519. PMID: 36010596; PMCID: PMC9406519.

  3. Jelinek T, Bezdekova R, Zihala D, Sevcikova T, Anilkumar Sithara A, Pospisilova L, Sevcikova S, Polackova P, Stork M, Knechtova Z, Venglar O, Kapustova V, Popkova T, Muronova L, Chyra Z, Hrdinka M, Simicek M, Garcés JJ, Puig N, Cedena MT, Jurczyszyn A, Castillo JJ, Penka M, Radocha J, Mateos MV, San-Miguel JF, Paiva B, Pour L, Rihova L, Hajek R. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma. J Clin Oncol. 2022 Oct 31:JCO2201226. doi: 10.1200/JCO.22.01226. Epub ahead of print. PMID: 36315921.

  4. Haertle L, Barrio S, Munawar U, Han S, Zhou X, Simicek M, Vogt C, Truger M, Alonso Fernandez R, Steinhardt M, Weingart J, Snaurova R, Nerreter S, Teufel E, Garitano-Trojaola A, Da Viá M, Ruiz-Heredia Y, Rosenwald A, Bolli N, Hajek R, Raab P, Raab MS, Weinhold N, Haferlach C, Haaf T, Martinez-Lopez J, Einsele H, Rasche L, Kortüm KM. Single Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma. Clin Cancer Res. 2022 Oct 25:CCR-22-1161. doi: 10.1158/1078-0432.CCR-22-1161. Epub ahead of print. PMID: 36282272.

  5. Vdovin A, Jelinek T, Zihala D, Sevcikova T, Durech M, Sahinbegovic H, Snaurova R, Radhakrishnan D, Turi M, Chyra Z, Popkova T, Venglar O, Hrdinka M, Hajek R, Simicek M. The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma. Nat Commun. 2022 Nov 10;13(1):6820. doi: 10.1038/s41467-022-34654-2. PMID: 36357400.

Top

 

 

 

2021 Selected Publications:

 

  1. B. Motais, S. Charvátová, Z. Walek, M. Hrdinka, R. Smolarczyk, T. Cichoń, J. Czapla, S. Giebel, M. Šimíček, T. Jelínek, T. Ševčíková, J. Sobotka, Z. Kořístek, R. Hájek and J.R. Bagó, 2021. Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment. Cells; 10(5), 967; https://doi.org/10.3390/cells10050967 

  2. T. Jelinek, T. Sevcikova, D. Zihala, T. Popkova, V. Kapustova, L. Broskevicova, L. Capkova, L. Rihova, R. Bezdekova, S. Sevcikova, V. Zidlik, M. Havel, H. Plonkova, A. Jungova, J. Minarik, M. Stork, L. Pour, P. Pavlicek, I. Spicka, V. Maisnar, J. Radocha, M. Simicek & R. Hajek , 2021. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia; https://doi.org/10.1038/s41375-021-01343-w;

  3. Zátopková M., Ševčíková T., Fanfani V., Chyra Z., Rihova L., Bezdekova R., Žihala D., Growková K., Filipova J., Černá L., Broskevičová L., Kryukov F., Minařík J., Smejkalová J., Maisnar V., Harvanová L., Pour L., Jungova A., Popková T., Bago J.R., Anilkumar Sithara A., Hrdinka M., Jelinek T., Šimíček M., Stracquadanio G., Hajek R.. Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine. Blood Adv. 2021 Sep 9. doi: 10.1182/bloodadvances.2020003876. Epub ahead of print. PMID: 34500459.

Top

 

 

2020 Selected Publications:

  1. B. Motais , S. Charvátová , M. Hrdinka , M. Šimíček , T. Jelínek , T. Ševčíková  , Z. Kořístek , R. Hájek , J. R. Bagó 2020. "A Bird's-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers". Cancers (Basel);12(5):1333. 

  2. H. Sahinbegovic, T. Jelinek , M. Hrdinka, J.R. Bago, M. Turi , T. Sevcikova, A. Kurtovic-Kozaric , R. Hajek, M. Simicek 2020. "Intercellular Mitochondrial Transfer in the Tumor Microenvironment". Cancers (Basel);12(7):1787.

Top

 

 

 

2019 Selected Publications:

  1. Garcés, J.J., Simicek M., Vicari M., Brozova L., Burgos L., Bezdekova R., Alignani D., Calasanz M.J., Growkova K., Goicoechea I., Agirre X., Pour L., Prosper F., Rios R., Martinez-Lopez J., Millacoy P., Palomera L., Del Orbe R., Perez-Montaña A., Garate S., Blanco L., Lasa M., Maiso P., Flores-Montero J., Sanoja-Flores L., Chyra Z., Vdovin A. , Sevcikova T., Jelinek T., Botta C., El Omri H., Keats J., Orfao A., Hajek R., San-Miguel J.F., Paiva B.. 2019. “Transcriptomic Profiling of Circulating Tumor Cells (CTCs) in Multiple Myeloma (MM): A New Model to Understand Disease Dissemination.” Blood 132(Suppl 1):245 LP – 245.

  2. Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2019 Jan 19;393(10168):253-264

  3. Jelinek T, Mihalyova J, Kascak M, Duras J, Popkova T, Benkova K, Richterova P, Plonkova H, Zuchnicka J, Broskevicova L, Huvarova L, Cerna L, Growkova K, Simicek M, Havel M, Gumulec J, Navratil M, Koristek Z, Paiva B, Hajek R. Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t[11;14]. Am J Hematol. 2019 Jan;94(1):E35-E37

  4. Jurczyszyn A, Castillo JJ, Avivi I, Czepiel J, Davila J, Vij R, Fiala MA, Gozzetti A, Grząśko N, Milunovic V, Hus I, Mądry K, Waszczuk-Gajda A, Usnarska-Zubkiewicz L, Dębski J, Atilla E, Beksac M, Mele G, Sawicki W, Jayabalan D, Charliński G, Gyula Szabo A, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Crusoe E, Hungria V, Richardson P, Laubach J, Guerrero-Garcia T, Liu J, Vesole DH. Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leuk Lymphoma. 2019 Jan;60(1):118-123.

  5. Gonzalez-McQuire S, Dimopoulos MA, Weisel K, Bouwmeester W, Hájek R, Campioni M, Bennison C, Xu W, Pantiri K, Hensen M, Terpos E, Knop S. Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making. MDM Policy Pract. 2019 Jan 17;4(1):2381468318814253.

  6. Steiner, N; Hajek, R; Nachbaur, D; Borjan, B; Sevcikova, S; Gobel, G; Gunsilius, E. Levels of CEACAM6 in Peripheral Blood Are Elevated in Patients with Plasma Cell Disorders: A Potential New Diagnostic Marker and a New Therapeutic Target? DISEASE MARKERS 2019;1806034.

  7. Ludwig H, Moreau P, Dimopoulos MA, Mateos MV, Kaiser M, Hajek R, Feng S, Cocks K, Buchanan J, Weisel K. Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer J. 2019 Feb 22;9(3):23.

  8. Jurczyszyn A, Davila J, Kortüm KM, Jayabalan DS, Vij R, Fiala M, Milunovic V, Chim CS, Wiśniewska-Piąty K, Waszczuk-Gajda A, Crusoe E, Hajek R, Robak P, Raźny M, Zawirska D, Bittrich M, Nahi H, Liu J, Castillo JJ, Vesole DH. Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases. Leuk Lymphoma. 2019 Feb;60(2):471-476.

  9. Radocha J, Hájek R, Brožová L, Pour L, Špička I, Minařík J, Gregora E, Jungová A, Jelínek T, Heindorfer A, Sýkora M, Maisnar V. Simplified novel prognostic score for real-life older adults with multiple myeloma-registry-based analysis. Ann Hematol. 2019 Apr;98(4):951-962.

  10. Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos M, Hajek R, Pour L, Jurczyszyn A, Qiu L, Klippel Z, Zahlten-Kumeli A, Osman M, Paiva B, San-Miguel J. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2019 May 2;133(18):1953-1963.

  11. Maisnar V, Stefanikova Z, Spicka I, Pour L, Minarik J, Flochova M, Radocha J, Gregora E, Stecova N, Jelinek T, Jungova A, Kralikova E, Brozova L, Hajek R. Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. Neoplasma. 2019 May 23;66(3):499-505.

  12. Jelinek T, Adamusova L, Popkova T, Tvrda I, Smejkalova J, Simicek M, Salounova D, Kascak M, Mihalyova J, Plonkova H, Duras J, Navratil M, Hajek R, Koristek Z. Cytarabine + G-CSF is more effective than cyclophosphamide + G-CSF as a stem cell mobilization regimen in multiple myeloma. Bone Marrow Transplant. 2019 Jul;54(7):1107-111.

  13. Thomsen H, Chattopadhyay S, Weinhold N, Vodicka P, Vodickova L, Hoffmann P, Nöthen MM, Jöckel KH, Langer C, Hajek R, Hallmans G, Pettersson-Kymmer U, Ohlsson C, Späth F, Houlston R, Goldschmidt H, Hemminki K, Försti A. Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS): comparison with multiple myeloma. Leukemia. 2019 Jul;33(7):1817-1821.

  14. Sevcikova S, Minarik J, Stork M, Jelinek T, Pour L, Hajek R. Extramedullary disease in multiple myeloma - controversies and future directions. Blood Rev. 2019 Jul;36:32-39.

  15. Minarik J, Pour L, Maisnar V, Spicka I, Jungova A, Jelinek T, Brozova L, Krhovska P, Scudla V, Hajek R. Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019 Sep;163(3):279-283.

  16. Spicka I, Ocio EM, Oakervee HE, Greil R, Banh RH, Huang SY, D'Rozario JM, Dimopoulos MA, Martínez S, Extremera S, Kahatt C, Alfaro V, Carella AM, Meuleman N, Hájek R, Symeonidis A, Min CK, Cannell P, Ludwig H, Sonneveld P, Mateos MV. Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma. Ann Hematol. 2019 Sep;98(9):2139-2150.

  17. Ludwig H, Pönisch W, Knop S, Egle A, Hinke A, Schreder M, Lechner D, Hajek R, Gunsilius E, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Rumpold H, Pour L, Jelinek T, Krenosz KJ, Meckl A, Nolte S, Melchardt T, Greil R, Zojer N. Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population. Leuk Lymphoma. 2019 Sep 26:1-10.

  18. Janikova A, Chloupkova R, Campr V, Klener P, Hamouzova J, Belada D, Prochazka V, Pytlik R, Pirnos J, Duras J, Mocikova H, Bortlicek Z, Kopalova N, Mayer J, Trneny M. First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. Ann Hematol. 2019 Aug;98(8):1961-1972.

  19. Ludwig H, Poenisch W, Knop S, Egle A, Schreder M, Lechner D, Hajek R, Gunsilius E, Krenosz KJ, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Melchardt T, Greil R, Zojer N. Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. Br J Cancer. 2019 Oct;121(9):751-757.

  20. Hájek R, Delforge M, Raab MS, Schoen P, DeCosta L, Spicka I, Radocha J, Pour L, Gonzalez-McQuire S, Bouwmeester W. Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma. Br J Haematol. 2019 Nov;187(4):447-458

  21. Bonello F, Pulini S, Ballanti S, Gentile M, Spada S, Annibali O, Omedé P, Ronconi S, Cangialosi C, Podda L, Palmas A, Malfitano A, Rivoli G, Belotti A, Ciambelli F, Vincelli ID, Cafro AM, Innao V, Palumbo A, Sonneveld P, Spencer A, Hájek R, Boccadoro M, Gay F. Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis. Cancers (Basel). 2019 Nov 5;11(11). pii: E1735.

  22. Hrdinka M, Yabal M. Inhibitor of apoptosis proteins in human health and disease. Genes Immun. 2019 Nov;20(8):641-650.

  23. Moreau P, Sonneveld P, Boccadoro M, Cook G, Mateos MV, Nahi H, Goldschmidt H, Dimopoulos MA, Lucio P, Bladé J, Delforge M, Hajek R, Ludwig H, Facon T, San Miguel JF, Einsele H.  Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. Haematologica. 2019 Dec;104(12):2358-2360.

  24. Kral, Z; Michalka, J; Mocikova, H; Markova, J; Sykorova, A; Belada, D; Jungova, A; Vokurka, S; Lukasova, M; Prochazka, V; Duras, J; Hajek, R; Dusek, L; Drgona, L; Ladicka, M; Ballova, V; Vranovsky, A. Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia. JOURNAL OF CANCER, 10 (21):5041-5048.

  25. Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019 Jan 19;393(10168):229-240. 

  26. Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019 Nov 14. pii: S0140-6736(19)32556-5

  27. Scully M, Cataland SR, Peyvandi F, Coppo P, Knobl P, Kremer Hovinga JA et al.; HERCULES Investigators. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med 2019; 380(4): 335-346.

     

Top

 

 

 

 

2018 Selected Publications:

  1. Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner HW, Caers J, Gramatzki M, van de Donk N, Oliva S, Zamagni E, Garderet L, Straka C, Hajek R, Ludwig H, Einsele H, Dimopoulos M, Boccadoro M, Kröger N, Cavo M, Goldschmidt H, Bruno B, Sonneveld P. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica. 2018 Feb;103(2):197-211.

  2. Mihalyova J, Jelinek T, Growkova K, Hrdinka M, Simicek M, Hajek R. Venetoclax: a newwavein   hematooncology. Exp Hematol. 2018 May;61:10-25

  3. Morrow ME, Morgan MT, Clerici M, Growkova K, Yan M, Komander D, Sixma TK, Simicek M, Wolberger C. Active site alanine mutations convert deubiquitinases into high-affinity ubiquitin-binding proteins. EMBO Rep. 2018 Aug 27.pii: e45680.

  4. Buske C, Sadullah S, Kastritis E, Tedeschi A, García-Sanz R, Bolkun L, Leleu X, Willenbacher W, Hajek R, Minnema MC, Cheng M, Bilotti E, Graef T, Dimopoulos MA; European Consortium for Waldenström's Macroglobulinemia.Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. Lancet Haematol. 2018 Jul;5(7):e299-e309.

  5. Gavriatopoulou M, Musto P, Caers J, Merlini G, Kastritis E, van de Donk N, Gay F, Hegenbart U, Hajek R, Zweegman S, Bruno B, Straka C, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M, Terpos E. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018 Sep;32(9):1883-1898.

  6. Usmani SZ, Hoering A, Cavo M, Miguel JS, Goldschimdt H, Hajek R, Turesson I, Lahuerta JJ, Attal M, Barlogie B, Lee JH, Kumar S, Lenhoff S, Morgan G, Rajkumar SV, Durie BGM, Moreau P. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project. Blood Cancer J. 2018 Nov 23;8(12):123.

  7. Hrdinka M, Schlicher L, Dai B, Pinkas DM, Bufton JC, Picaud S, Ward JA, Rogers C, Suebsuwong C, Nikhar S, Cuny GD, Huber KV,Filippakopoulos P, Bullock AN,Degterev A, Gyrd-Hansen M. Small molecule inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling. EMBO J. 2018 Sep 3;37(17).

  8. Steklov, M. Pandolfi, S., Baietti, M., Batiuk, A., Carai, P., Najm, P., Zhang, M., Jang, H., Renzi, F., Cai, Y., Asbagh, L., Pastor, L., De Troyer, M., Simicek, M., Radaelli, E., Brems, H., Legius, E., Tavernier, J., Gevaert, K., Impens, F., Messiaen, L., Nussinov, R., Heymans, S., Eyckerman, S., Sablina A. Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination. Science. 2018 Dec 7;362(6419):1177-1182.

Top

 

 

 

 

2017 Selected Publications:

  1. Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górnik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2017 Jan;31(1):107-114.

  2. Steiner N, Borjan B, Hajek R, Jöhrer K, Göbel G, Willenbacher W, Kern J, Gunsilius E, Untergasser G. Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma. Oncotarget. 2017 Apr 21;8(34):56243-56254.

  3. Mikulasova A, Wardell CP, Murison A, Boyle EM, Jackson GH, Smetana J, Kufova Z, Pour L, Sandecka V, Almasi M, Vsianska P, Gregora E, Kuglik P, Hajek R, Davies FE, Morgan GJ, Walker BA. The spectrum of static mutations in monoclonal gammopathy of undetermined significanceindicates a less komplex genomic landscape than that in multiple myeloma. Haematologica.  2017 Sep;102(9):1617-1625.

  4. Ševčíková T, Growková K, Kufová Z, Filipová J, Vrublová P, Jelínek T, Kořístek Z, Kryukov F, Kryukova E, Hájek R. Biobanking strategy and sample preprocessing for integrative research in monoclonal gammopathies. J Clin Pathol. 2017 Oct;70(10):847-853.

  5. Jelinek T, Bezdekova R, Zatopkova M, Burgos L, Simicek M, Sevcikova T, Paiva B, Hajek R. Current applications of multiparameter flow cytometry in plasma cell disorders. Blood Cancer J. 2017 Oct 20;7(10):e617. IF 6,126

  6. Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1327-1337.

  7. Jelinek T, Mihalyova J, Kascak M, Duras J, Hajek R. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017. Immunology. 2017 Nov;152(3):357-371.

  8. Growková K, Kryukova E, Kufová Z, Filipová J, Ševčíková T, Říhová L, Kaščák M, Kryukov F, Hájek R. Waldenström's macroglobulinemia: Two malignant clones in a monoclonal disease? Molecular background and clinical reflection. Eur J Haematol. 2017 Dec;99(6):469-478

  9. Jelinek T, Kryukova E, Kufova Z, Kryukov F, Hajek R. Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity. Hematol Oncol. 2017 Dec;35(4):408-419. 

Top

 

 

 

 

2016 Selected Publications:

  1. Radocha J, Pour L, Pika T, Maisnar V, Špička I, Gregora E, Krejčí M, Minařík J, Machálková K, Straub J, Pavlíček P, Hájek R, Žák P. Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myelomadisease relapse. Eur J Haematol. 2016 Feb;96(2):119-27. IF 2,544

  2. Kryukova E, Kryukov F, Hajek R. Centrosome amplification and clonal evolution in multiple myeloma: Short review. Crit Rev Oncol Hematol. 2016 Feb;98:116-21. IF IF 5,039

  3. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosinol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer HH, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016 Jan; 17(1):27-38. IF 26,509

  4. Magarotto V, Bringhen S, Offidani M, Benevolo G, Patriarca F, Mina R, Falcone AP, De Paoli L, Pietrantuono G, Gentili S, Musolino C, Giuliani N, Bernardini A, Conticello C, Pulini S, Ciccone G, Maisnar V, Ruggeri M, Zambello R, Guglielmelli T, Ledda A, Liberati AM, Montefusco V, Hajek R, Boccadoro M, Palumbo A. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood. 2016 Mar 3;127(9):1102-8. IF 11,841

  5. Jelinek, T, Kufova Z, Hajek R. Immunomodulatory drugs in AL amyloidosis. Crit Rev Oncol Hematol. 2016 Mar;99:249-60. IF 5,039

  6. Jelinek T, Hajek R. Monoclonal antibodies - A new era in the treatment of multiple myeloma. Blood Rev. 2016 Mar;30(2):101-10. IF 6,627

  7. Kryukov F, Nemec P, Radova L, Kryukova E, Okubote S, Minarik J, Stefanikova Z, Pour L, Hajek R. Centrosome associated genes pattern for risk sub-stratification in multiple myeloma. J Transl Med. 2016 May 28;14(1):150. IF 3,694

  8. Besse L, Sedlarikova L, Greslikova H, Kupska R, Almasi M, Penka M, Jelinek T, Pour L, Adam Z, Kuglik P, Krejci M, Hajek R, Sevcikova S. Cytogenetics in multiple myeloma patients progressing into extramedullary disease. Eur J Haematol. 2016 Jul;97(1):93-100. IF 2,544

  9. Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Xiu L, Cakana A, Parekh T, San-Miguel JF. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer. 2016 Jul 1;122(13):2050-6. IF 5,649

  10. Kryukov F, Kryukova E, Brozova L, Kufova Z, Filipova J, Growkova K, Sevcikova T, Jarkovsky J, Hajek R. Does AL amyloidosis have a unique genomic profile? Gene expression profiling meta-analysis and literature overview. Gene. 2016 Oct 15;591(2):490-8. IF 2,319

  11. Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špička I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P.Carfilzomib significantly improves the progression free survival of high-risk patients in multiple myeloma. Blood. 2016 Sep 1;128(9):1174-80 IF 11,847

  12. Mikulasova A, Smetana J, Wayhelova M, Janyskova H, Sandecka V, Kufova Z, Almasi M, Jarkovsky J, Gregora E, Kessler P, Wrobel M, Walker BA, Wardell CP, Morgan GJ, Hajek R, Kuglik P. Genome-wide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance. Eur J Haematol. 2016 Dec;97(6):568-575. IF 2,544

  13. Thangavadivel S, Zelle-Rieser C, Olivier A, Postert B, Untergasser G, Kern J, Brunner A, Gunsilius E, Biedermann R, Hajek R, Pour L, Willenbacher W, Greil R, Jöhrer K. CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma. Oncotarget. 2016 Nov 29;7(48):78605-78618. IF 5,415

  14. MIKULÁŠOVÁ, A., J. SMETANA, M. WAYHELOVÁ, H. JANYŠKOVÁ, S.A. OKUBOTE, R. HÁJEK a P. KUGLÍK. Whole genome amplification effect on segmental copy-number changes and copy-number neutral loss of heterozygosity analysis by oligonucleotide-based array-comparative genomic hybridization in human myeloma cell line. International journal of clinical and experimental pathology [online]. 2016, vol. 9, no. 7, p. 6965-6976. IF 1,673

  15. SMETANA, J., P. KUGLÍK, H. GREŠLÍKOVÁ, R. KUPSKÁ, P. NĚMEC, A. MIKULÁŠOVÁ, I. VALÁŠKOVÁ, J. OPPELT, M. ALMÁŠI, M. KREJČÍ, Z. ADAM, L. POUR a R. HÁJEK. Clonal cytogenetics changes in progression of multiple myeloma to extramedullary relapse and plasmocellular leukemia: a case report. International journal of clinical and experimental pathology [online]. 2016, vol. 9, no. 1, p. 49-60. IF 1,673

  16. Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, Siniscalchi A, Magarotto V, Pour L, Carella A, Malfitano A, Petrò D, Evangelista A, Spada S, Pescosta N, Omedè P, Campbell P, Liberati AM, Offidani M, Ria R, Pulini S, Patriarca F, Hajek R, Spencer A, Boccadoro M, Palumbo A. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015 Dec;16(16):1617-29 IF 24,69

  17. Filipova J, Rihova L, Vsianska P, Kufova Z, Kryukova E, Kryukov F, Hajek R. Flow cytometry in immunoglobulin light chain amyloidosis: Short review. Leuk Res. 2015 Jul 13. pii: S0145-2126(15)30345-3. IF 2,35

  18. Pika T, Lochman P, Sandecka V, Maisnar V, Minarik J, Tichy M, Zapletalova J, Solcova L, Scudla V, Hajek R. Immunoparesis in MGUS - Relationship of uninvolved immunoglobulin pair suppression and polyclonal immunoglobuline levels to MGUS risk categories. Neoplasma. 2015;62(5):827-32. 1,87

  19. Ludwig H, Greil R, Masszi T, Spicka I, Shpilberg O, Hajek R, Dmoszynska A, Paiva B, Vidriales MB, Esteves G, Stoppa AM, Robinson D Jr, Chaturvedi S, Ataman O, Enny C, Feng H, van de Velde H, Viterbo L. Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up. Br J Haematol. 2015 Nov;171(3):344-54. IF 4,942

  20. Drandi D, Kubiczkova-Besse L, Ferrero S, Dani N, Passera R, Mantoan B, Gambella M, Monitillo L, Saraci E, Ghione P, Genuardi E, Barbero D,Omedè P, Barberio D, Hajek R, Vitolo U, Palumbo A, Cortelazzo S, Boccadoro M, Inghirami G, Ladetto M. Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR. J Mol Diagn. 2015 Nov;17(6):652-60. IF 4,85

  21. Palumbo A, Gay F, Cavallo F, Di Raimondo F, Larocca A, Hardan I, Nagler A, Petrucci MT, Hajek R, Pezzatti S, Delforge M, Patriarca F, Donato F,Cerrato C, Nozzoli C, Yu Z, Boccadifuoco L, Caravita T, Benevolo G, Guglielmelli T, Vincelli D, Jacques C, Dimopoulos MA, Ciccone G, Musto P,Corradini P, Cavo M, Boccadoro M. Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2015 Oct 20;33(30):3459-66. IF 18,43

  22. Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, van de Donk NW, Bruno B, Sezer O, Broijl A, Bringhen S, Beksac M, Larocca A, Hajek R, Musto P, Johnsen HE, Morabito F, Ludwig H, Cavo M, Einsele H, Sonneveld P, Dimopoulos MA, Palumbo A; European Myeloma Network. European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. Haematologica. 2015 Oct;100(10):1254-66. IF 5,81

  23. Sedlaříková L, Bešše L, Novosadová S, Kubaczková V, Radová L, Staník M, Krejčí M, Hájek R, Ševčíková S. MicroRNAs in urine are not biomarkers of multiple myeloma. J Negat Results Biomed. 2015 Sep 23;14(1):16. IF 1,47

  24. Besse L, Sedlarikova L, Kryukov F, Nekvindova J, Radova L, Slaby O, Kuglik P, Almasi M, Penka M, Krejci M, Adam Z, Pour L, Sevcikova S, Hajek R. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma. PLoS One. 2015 Sep 21;10(9):e0137294. IF 3,23

  25. Jelinek T, Kryukov F, Rihova L, Hajek R. Plasma cell leukemia: from biology to treatment. Eur J Haematol. 2015 Jul;95(1):16-26. IF 2,41

  26. Fiserova B, Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S. The miR-29 family in hematological malignancies. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Jun;159(2):184-91. IF 1,2

  27. Sevcikova S, Paszekova H, Besse L, Sedlarikova L, Kubaczkova V, Almasi M, Pour L, Hajek R. Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Jun;159(2):288-93. IF 1,66

  28. Minarik J, Pavlicek P, Pour L, Pika T, Maisnar V, Spicka I, Jarkovsky J, Krejci M, Bacovsky J, Radocha J, Straub J, Kessler P, Wrobel M, Walterova L, Sykora M, Obernauerova J, Brozova L6, Gregora E, Adamova D, Gumulec J, Adam Z, Scudla V, Hajek R; Czech Myeloma Group. Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy. PLoS One. 2015 Apr 14;10(4):e0123866. eCollection 2015. IF 3,53

  29. Všianská P, Říhová L, Varmužová T, Suská R, Kryukov F, Mikulášová A, Kupská R, Penka M, Pour L, Adam Z, Hájek R. Analysis of B-cell subpopulations in monoclonal gammopathies. Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):e61-71. IF 1,13

  30. Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, Offidani M, McCarthy P, Evangelista A, Lonial S, Zweegman S, Musto P, Terpos E, Belch A, Hajek R, Ludwig H, Stewart AK, Moreau P, Anderson K, Einsele H, Durie BG, Dimopoulos MA, Landgren O, San Miguel JF, Richardson P, Sonneveld P, Rajkumar SV. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015 Mar 26;125(13):2068-74. IF 9,78

  31. Kubiczkova Besse L, Sedlarikova L, Kryukov F, Nekvindova J, Radova L, Almasi M, Pelcova J, Minarik J, Pika T, Pikalova Z, Scudla V, Krejci M, Adam Z, Pour L, Hajek R, Sevcikova S. Combination of serum microRNA-320a and microRNA-320b as a marker for Waldenström macroglobulinemia. Am J Hematol. 2015 Mar;90(3):E51-2. IF 3,477

  32. Piskacek M, Vasku A, Hajek R, Knight A. Shared structural features of the 9aaTAD family in complex with CBP. Mol Biosyst. 2015 Mar;11(3):844-51. IF 3,183

  33. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; the ASPIRE Investigators. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. N Engl J Med. 2015 Jan 8;372(2):142-52. IF 54.42

Top

 

 

 

 

2015 Selected Publications:

  1. Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, Siniscalchi A, Magarotto V, Pour L, Carella A, Malfitano A, Petrò D, Evangelista A, Spada S, Pescosta N, Omedè P, Campbell P, Liberati AM, Offidani M, Ria R, Pulini S, Patriarca F, Hajek R, Spencer A, Boccadoro M, Palumbo A. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015 Dec;16(16):1617-29.

  2. Palumbo A, Gay F, Cavallo F, Di Raimondo F, Larocca A, Hardan I, Nagler A, Petrucci MT, Hajek R, Pezzatti S, Delforge M, Patriarca F, Donato F,Cerrato C, Nozzoli C, Yu Z, Boccadifuoco L, Caravita T, Benevolo G, Guglielmelli T, Vincelli D, Jacques C, Dimopoulos MA, Ciccone G, Musto P,Corradini P, Cavo M, Boccadoro M. Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2015 Oct 20;33(30):3459-66.

  3. Besse L, Sedlarikova L, Kryukov F, Nekvindova J, Radova L, Slaby O, Kuglik P, Almasi M, Penka M, Krejci M, Adam Z, Pour L, Sevcikova S, Hajek R. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma. PLoS One. 2015 Sep 21;10(9):e0137294

  4. Kubiczkova Besse L, Sedlarikova L, Kryukov F, Nekvindova J, Radova L, Almasi M, Pelcova J, Minarik J, Pika T, Pikalova Z, Scudla V, Krejci M, Adam Z, Pour L, Hajek R, Sevcikova S. Combination of serum microRNA-320a and microRNA-320b as a marker for Waldenström macroglobulinemia. Am J Hematol. 2015 Mar;90(3):E51-2.

  5. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; the ASPIRE Investigators. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. N Engl J Med. 2015 Jan 8;372(2):142-52.

  6. Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, Larocca A, van der Holt B, Musto P, Offidani M, Petrucci MT, Evangelista A, Zweegman S, Nooka AK, Spencer A, Dimopoulos MA, Hajek R, Cavo M, Richardson P, Lonial S, Ciccone G, Boccadoro M, Anderson K, Barlogie B, Sonneveld P, McCarthy PL. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014 Mar;15(3):333-42.

Top

 

 

 

 

2014 Selected Publications:

  1. Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC, Dimopoulos MA, Richardson PG, Cavo M, Spencer A, Stewart AK, Shimizu K, Lonial S, Sonneveld P, Durie BG, Moreau P, Orlowski RZ. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patiens with myeloma not eligible for standard autologous stem-cell transplantation. J ClinOncol. 2014 Feb 20;32(6):587-600.

  2. Svachova H, Kryukov F, Kryukova E, Sevcikova S, Nemec P, Greslikova H, Rihova L, Kubiczkova L, Hajek R. Nestin expression throughout multistep pathogenesis of multiple myeloma. Br J Haematol. 2014 Mar;164(5):701-9.

  3. Ludwig H, Miguel JS, Dimopoulos MA, Palumbo A,GarciaSanz R, Powles R, Lentzsch S, Ming Chen W, Hou J, Jurczyszyn A, Romeril K, Hajek R, Terpos E,Shimizu K, Joshua D, Hungria V, RodriguezMorales A, Ben-Yehuda D, Sondergeld P, Zamagni E, Durie B. International Myeloma Working Group recommendations for global myeloma care. Leukemia. 2014 May;28(5):981-92.

  4. Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L, Sandecka V, Adam Z, Krejci M, Kuglik P, Hajek R. Soft-tissueextra medullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014 Feb;99(2):360-4.

Top